Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Oncolytics Bio (ONC.TO)

Oncolytics Bio (ONC.TO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 102,445
  • Shares Outstanding, K 40,492
  • Annual Sales, $ 0 K
  • Annual Income, $ -33,123 K
  • 60-Month Beta 1.62
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.37
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -1.27
  • Most Recent Earnings N/A on 03/31/20
  • Next Earnings Date 08/11/20
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

    TSX Biotechnology

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.21
  • Number of Estimates 1
  • High Estimate -0.21
  • Low Estimate -0.21
  • Prior Year -0.26
  • Growth Rate Est. (year over year) +19.23%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.50 +1.20%
on 06/29/20
3.09 -18.12%
on 06/04/20
-0.48 (-15.95%)
since 06/03/20
3-Month
1.81 +39.78%
on 04/24/20
4.02 -37.06%
on 05/19/20
+0.47 (+22.82%)
since 04/03/20
52-Week
0.48 +427.08%
on 10/02/19
7.84 -67.73%
on 12/31/19
+0.28 (+12.44%)
since 07/03/19

Most Recent Stories

More News
Cancer Immunotherapy Gets Boost from Newly Engineered Nanoparticles

, /PRNewswire/ --   – In a major step forward, engineers from have designed nanoparticles that stimulate the immune system, helping it to attack tumors. This could contribute significantly to other...

RHHBY : 43.7900 (-0.55%)
XYNO : 0.7800 (+267.92%)
CANF : 2.00 (+3.09%)
ONCY : 1.8600 (-2.62%)
ONC.TO : 2.53 (+0.40%)
Advancements in Breast Cancer Research & Clinical Studies Producing Optimism for New Treatments

, /PRNewswire/ -- The triple negative breast cancer (TNBC) treatment market to grow at stellar CAGR through 2026. A  from Cole Market Research has stated that the ongoing advancements in cancer research...

ONCY : 1.8600 (-2.62%)
ONC.TO : 2.53 (+0.40%)
GNPX : 3.03 (-1.30%)
CRDF : 4.31 (-9.45%)
MRK : 78.78 (+0.84%)
LLY : 163.87 (+0.35%)
Oncolytics Biotech® Announces Investigator Sponsored Phase 2 Trial Evaluating Pelareorep-anti-PD-1 Combination Treatment in Triple-Negative Breast Cancer

and , /PRNewswire/ --

ONCY : 1.8600 (-2.62%)
ONC.TO : 2.53 (+0.40%)
Oncolytics Biotech® Announces Investigator Sponsored Phase 2 Trial Evaluating Pelareorep-anti-PD-1 Combination Treatment in Triple-Negative Breast Cancer

SAN DIEGO and CALGARY, Alberta , June 25, 2020 /PRNewswire/ -- Oncolytics Biotech ®  Inc. (NASDAQ: ONCY) (TSX: ONC), today announced a new investigator-sponsored triple-negative...

ONCY : 1.8600 (-2.62%)
ONC.TO : 2.53 (+0.40%)
Clinical Trials for new Therapies Providing Hope for Metastatic Breast Cancer Patients

, /PRNewswire/ -- Metastatic breast cancer (also called stage IV) is breast cancer that has spread to another part of the body, most commonly the liver, brain, bones, or lungs. Metastatic disease is NOT...

ONCY : 1.8600 (-2.62%)
ONC.TO : 2.53 (+0.40%)
PFE : 34.51 (+2.28%)
LLY : 163.87 (+0.35%)
NVTA : 31.72 (+4.07%)
CLVS : 6.61 (-1.20%)
CORT : 17.18 (+0.53%)
Oncolytics Biotech® Doses First Patient in Phase 2 BRACELET-1 Study Evaluating Pelareorep-Based Combination Therapies in Metastatic Breast Cancer

and , /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), today announced the first patient has been dosed in the Company's phase 2 study of pelareorep-based combination therapies in...

ONCY : 1.8600 (-2.62%)
ONC.TO : 2.53 (+0.40%)
PFE : 34.51 (+2.28%)
Oncolytics Biotech® Doses First Patient in Phase 2 BRACELET-1 Study Evaluating Pelareorep-Based Combination Therapies in Metastatic Breast Cancer

SAN DIEGO and CALGARY, Alberta , June 23, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), today announced the first patient has been dosed in the Company's phase 2 study...

ONCY : 1.8600 (-2.62%)
ONC.TO : 2.53 (+0.40%)
Oncolytics Biotech® Establishes New At-The-Market Facility

and , /PRNewswire/ -- Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that it has entered into...

ONCY : 1.8600 (-2.62%)
ONC.TO : 2.53 (+0.40%)
Oncolytics Biotech® Establishes New At-The-Market Facility

SAN DIEGO, Calif. and CALGARY, Alberta , June 15, 2020 /PRNewswire/ -- Oncolytics Biotech ®  Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered...

ONCY : 1.8600 (-2.62%)
ONC.TO : 2.53 (+0.40%)
Oncolytics Biotech® Provides Recap of Key Opinion Leader Call Highlighting the Induction of Rapid and Persistent Immune Responses With Systemic Pelareorep Treatment

and , /PRNewswire/ -- Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), today provided a recap of a Key Opinion Leader (KOL) call sponsored by Canaccord Genuity and held on . The call focused on recently...

ONCY : 1.8600 (-2.62%)
ONC.TO : 2.53 (+0.40%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Key Turning Points

2nd Resistance Point 2.57
1st Resistance Point 2.55
Last Price 2.53
1st Support Level 2.51
2nd Support Level 2.49

See More

52-Week High 7.84
Fibonacci 61.8% 5.03
Fibonacci 50% 4.16
Fibonacci 38.2% 3.29
Last Price 2.53
52-Week Low 0.48

See More

Business Summary

Oncolytics Biotech Inc is a development stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. Its clinical development plan has the approval of its products as quickly...

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar